Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Recruiting 4Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 4

Conditions

Breast Neoplasms 1215Neoplasms 1024Carcinoma, Non-Small-Cell Lung 747Prostatic Neoplasms 687Colorectal Neoplasms 590Lung Neoplasms 572Pancreatic Neoplasms 394Leukemia, Myeloid, Acute 394Neoplasm Metastasis 387Ovarian Neoplasms 370Multiple Myeloma 369Stomach Neoplasms 316Carcinoma, Hepatocellular 301Melanoma 281Brain Neoplasms 277Recurrence 273Squamous Cell Carcinoma of Head and Neck 267Head and Neck Neoplasms 237Endometrial Neoplasms 234Glioblastoma 233Triple Negative Breast Neoplasms 228Uterine Cervical Neoplasms 221Precursor Cell Lymphoblastic Leukemia-Lymphoma 221Lymphoma 221Sarcoma 201Hematologic Neoplasms 199Urinary Bladder Neoplasms 196Esophageal Neoplasms 190Carcinoma, Renal Cell 187Lymphoma, Non-Hodgkin 175

Interventions

durvalumab 1ceralasertib 1aflutinib 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Non Small Cell Lung Cancer NSCLC × 1 year × Clear all
NCT07169708 2026-05-20

A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)

Ono Pharmaceutical Co., Ltd.

Recruiting
100 enrolled
Thoracic

Non Small Cell Lung Cancer NSCLC

NCT06680050 2025-12-18

AUSTRAL

Mario Negri Institute for Pharmacological Research

Phase 2 Recruiting
21 enrolled
Thoracic

Non Small Cell Lung Cancer NSCLC

NCT07188480 2025-09-23

The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase NA Recruiting
10 enrolled
Thoracic

Non Small Cell Lung Cancer NSCLC

NCT07087223 2025-07-25

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Peking University Cancer Hospital & Institute

Phase 1/2 Recruiting
42 enrolled
Thoracic

Non Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡